All In Biotech

Drug Trial Radar · NCT06614322

SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.

Sensory Phenotyping to Enhance Neuropathic Pain Drug Development (SPENDD): A Randomized, Double-blinded Cross-over Clinical Trial Aimed at Investigating Whether Bedside Quantitative Sensory Testing Can Predict Response to Analgesics.

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 190 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

190

Planned (sponsor's estimate)

Start

Feb 2, 2026

Primary completion

Jun 1, 2028

Study completion Jun 1, 2028

Sponsor

Lead sponsor
University of RochesterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Beth Israel Deaconess Medical Center
First posted
Sep 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to determine whether quantitative sensory testing (QST) can be used to classify participants into pain sub-groups and predict who will respond best to certain pain treatments in participants with painful peripheral neuropathy. The analgesic effect is evaluated by measuring pain intensity and Patient Global Impression of Change (PGIC). This study is a 3-period cross-over trial. This means researchers will compare 3 different drugs (pregabalin, duloxetine, and placebo) over a period of 19 weeks. Participants will: * Undergo a quantitative sensory testing (QST) exam. * Provide a blood sample. * Complete questionnaires on the computer. * Take the study drug as instructed.

Conditions

  • Painful Peripheral Neuropathy
  • Diabetic Peripheral Neuropathic Pain (DPN)
  • Chemotherapy Induced Peripheral Neuropathy (CIPN)
  • Idiopathic Peripheral Neuropathy

Interventions

  • PregabalinDrug

    300mg/day pregabalin capsule

  • DuloxetineDrug

    60mg/day duloxetine capsule

  • PlaceboOther

    Placebo capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pain IntensityTime frame: From enrollment to end of treatment period at 4 weeks

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Beth Israel Deaconess Medical Center for Autonomic and Peripheral Nerve Disorders

    Boston, Massachusetts · Recruiting

  • Ichan School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • University of Rochester

    Rochester, New York · Recruiting

  • University of Pittsburgh

    Pittsburgh, Pennsylvania · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

  • University of Vermont

    Burlington, Vermont · Recruiting

  • VCU Medical Center

    Richmond, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.